Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
AE

AMEX · AEON

AEON Biopharma, Inc.

Healthcare · Biotechnology

$0.21

Up+$0.01 (+3.68%)

Updated Nov 4, 2026, 5:11 PM

SID Score

3.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
13.25M
P/E ratio
-4,343.36
Dividend yield
0.00%
52-week range
$0.18 – $1.45
Volume
1.08M
Avg. volume
188.91K

Price performance · AEON

AEON price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

AEON closed at $0.21 after 21 trading sessions, down 26.75% for the selected period.

Last close
$0.21
Period change
-26.75%
Period low
$0.21
Period high
$0.31
Daily close
View OHLC price history
AEON OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$0.2747$0.2747$0.2111$0.21221.08M
Nov 2, 2026$0.2768$0.2989$0.27$0.273323.99K
Oct 30, 2026$0.2844$0.29$0.27$0.274774.56K
Oct 29, 2026$0.264$0.31$0.264$0.2941.35M
Oct 28, 2026$0.2489$0.269$0.2439$0.264730.79K
Oct 27, 2026$0.24$0.2549$0.24$0.2483140.15K
Oct 26, 2026$0.235$0.2499$0.235$0.24110.49K
Oct 23, 2026$0.235$0.2433$0.2311$0.2399199.47K
Oct 22, 2026$0.2371$0.24$0.2327$0.2337113.64K
Oct 21, 2026$0.2362$0.2501$0.2362$0.2402145.66K
Oct 20, 2026$0.2377$0.2414$0.22$0.2315310.15K
Oct 19, 2026$0.2408$0.2489$0.231$0.231459.37K
Oct 16, 2026$0.236$0.2476$0.2311$0.232243.88K
Oct 15, 2026$0.2323$0.2519$0.2307$0.243400.7K
Oct 14, 2026$0.23$0.241$0.2245$0.22891.13M
Oct 13, 2026$0.2418$0.25$0.2251$0.22971.29M
Oct 12, 2026$0.2741$0.2836$0.2425$0.24561.08M
Oct 9, 2026$0.3101$0.3189$0.276$0.2761.63M
Oct 8, 2026$0.3115$0.3239$0.2922$0.311.13M
Oct 7, 2026$0.293$0.3329$0.285$0.31132.92M
Oct 6, 2026$0.2635$0.295$0.2635$0.28972.27M

Latest AEON news

The latest Smart Investors Daily articles mentioning AEON.

Stock researchCompany · Overview

AEON research

Overview

Company profile and research snapshot.

Company profile

AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
AEON recent ratings
DateFirmRatingTarget
Oct 1, 2026Lake StreetBuy—
Aug 14, 2026HC Wainwright & Co.Buy—
Oct 8, 2025Aegis CapitalBuy—
Oct 1, 2024HC Wainwright & Co.Buy—
Aug 14, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

AEON Biopharma Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

ALISO VIEJO, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today reported the grant of restricted stock units (“RSUs”) covering 150,000 shares of the Company’s common stock to one newly hired non-executive employee of the Company. The award was approved by the Company’s Compensat

Yahoo · Oct 5, 2026

AEON: Initiating Coverage – Imitation is a Sincere Form of Flattery: Seeking a Botox Biosimilar

By John Vandermosten, CFA NYSE: AEON READ THE FULL AEON RESEARCH REPORT We are initiating coverage of AEON Biopharma, Inc. (NYSE: AEON) with a valuation of $2.00 per share. This value is based on our estimates for successful development and commercialization of ABP-450, a botulinum toxinA (BoNT) similar to Botox and equivalent to Jeuveau, Nabota, and Nuceiva. AEON’s objective is to develop,

Yahoo · Sep 30, 2026

AEON Biopharma FDA Type 2b Meeting Feedback Clarifies Biosimilar Development Plan for ABP-450

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work AEON plans to submit an IND for CMAP pharmacodynamic study in the fourth quarter of 2026 AEON plans to leverage its analytical, pharmacodynamic, and existing comparative human evidence to support a potential streamlined development path ALISO VIEJO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEO

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By